Back to search

Article

Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case Report

2024-10-28

Abstract excerpt

<title>Abstract</title> <p>Cenobamate (CNB) is a newer anti-seizure medication (ASM) approved by Food and Drug Administration (FDA) for adjunctive treatment of focal onset seizures in adults. Preclinical data indicates that CNB may have broad spectrum anti-seizure properties. A recently published small case study has reported that CNB led to improvement in seizure frequency in patients with generalized epilepsy....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7fe4b2c1-1e68-586a-8b9e-3d20e9ac272d
DOI
10.21203/rs.3.rs-5321423/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case ReportDOI 10.21203/rs.3.rs-5321423/v1
Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long termSemantic proximity
Multi-centric Phase III, single-arm, open-label clinical study to assess clinical safety, tolerability, and efficacy of intravenous lacosamide in focal onset seizuresSemantic proximity
Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.Semantic proximity
Anesthetic management of a pediatric patient with Dravet syndrome: A case report.Semantic proximity
A case of migraine treatment in a patient with a clinical diagnosis of CHARGE syndrome using onabotulinum toxin A.Semantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval processSemantic proximity
Select a neighboring publication to make it the new centre.